PHARMACODYNAMICS Gintropin® is a genetically engineered growth hormone. Stimulates skeletal and somatic growth, and also has a pronounced effect on metabolic processes. Stimulates the growth of the bones of the skeleton, affecting the plate epiphysis tubular bones, bone metabolism. Helps normalize body structure by increasing muscle mass and reducing body fat. In
patients with growth hormone deficiency and osteoporosis, substitution
therapy leads to normalization of mineral composition and bone density. Increases the number and size of cells of muscles, liver, thymus gland, gonads, adrenals, thyroid gland. Stimulates
the transport of amino acids into the cell and the synthesis of
proteins, reduces the level of cholesterol, affecting the profile of
lipids and lipoproteins. Suppresses the release of insulin. Promotes the retention of sodium, potassium and phosphorus. Increases body weight, muscle activity and physical endurance.PHARMACOKINETICS
The absorption of somatropin after subcutaneous administration is 80%,
the maximum concentration in the blood plasma is achieved in 3-6 hours. Penetrates into well-perfused organs. Metabolized in the kidneys and liver. The volume of distribution of somatropin is 0.49-2.11 l / kg. It is excreted by the kidneys and with bile (including 0.1% unchanged). The half-life after subcutaneous administration is 3-5 hours.INDICATIONS
OF APPLICATION Growth retardation in children due to insufficient
growth hormone secretion, gonadal dysgenesis (Shereshevsky-Turner
syndrome), chronic renal failure (decreased kidney function by more than
50%) in the prepubertal period. In adults with confirmed congenital or
acquired hormone deficiency growth as a substitute therapyCONTRAINDICATIONS
Hypersensitivity, malignant neoplasms, active brain tumors, urgent
conditions (including conditions after heart operations, abdominal
cavity, acute respiratory failure), pregnancy and lactation (during the
period of treatment it is necessary to refuse breastfeeding)